The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences /
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Med...
Saved in:
| Main Authors: | , , |
|---|---|
| Corporate Authors: | , , |
| Format: | Electronic Conference Proceeding eBook |
| Language: | English |
| Published: |
Washington, D.C. :
The National Academies Press,
[2014]
|
| Subjects: | |
| Online Access: |
Full text (Emmanuel users only) |
| Summary: | Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB. |
|---|---|
| Item Description: | Title from PDF title page. |
| Physical Description: | 1 online resource (1 PDF file (xxi, 195 pages)) : illustrations |
| Bibliography: | Includes bibliographical references. |
| ISBN: | 9780309285964 0309285968 9780309285971 0309285976 |
| Source of Description, Etc. Note: | Version viewed June 30, 2014. |
| Funding Information Note: | This activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (HHSN26300023 [Under Base #HHSN263201200074I] and Contract No. N01-OD-4-2139 TO #276; HHSF22301026T [Under Base #HHSF223200810020I]), AbbVie Inc., American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome Fund, CDC Foundation, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co. Foundation, Eli Lilly and Company, FasterCures, Fondation Merieux, Friends of Cancer Research, GlaxoSmithKline, Johnson & Johnson, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Sanofi. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity. |